Search Results

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)

GPRC5D-Targeted CAR T-Cell Therapy for RRMM: Phase 1 Study Outcomes of BMS-986393 (CC-95266)

Updated results of BCMA/CD19 dual-targeting fast CAR-T GC012F dual-targeting CAR-T in RRMM

Updated results of BCMA/CD19 dual-targeting fast CAR-T GC012F dual-targeting CAR-T in RRMM

BMS' Breyanzi receives EC approval for r/r Large B-Cell Lymphoma post one prior therapy

BMS' Breyanzi receives EC approval for r/r Large B-Cell Lymphoma post one prior therapy

Highlights from Some of the ASH 2021 MRD Data

Highlights from Some of the ASH 2021 MRD Data

Phase 1 Dual-Targeting FasTCAR-T Cells for First-Line Tx of Transplant-Eligible High-Risk MM

Phase 1 Dual-Targeting FasTCAR-T Cells for First-Line Tx of Transplant-Eligible High-Risk MM

Bispecifics Part 4: The Science of Bispecific Antibodies

Bispecifics Part 4: The Science of Bispecific Antibodies

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Clinical Investigator Perspectives: The Most Relevant New Data Sets and Advances in Multiple Myeloma

Clinical Investigator Perspectives: The Most Relevant New Data Sets and Advances in Multiple Myeloma

Trials in Duchenne - BMS [PPMD's 2016 Connect Conference]

Trials in Duchenne - BMS [PPMD's 2016 Connect Conference]